Boston Scientific is recommended as a buy with a $109 target price, implying 14% upside, driven by robust demand and niche leadership. BSX outpaces market growth through focused M&A, strong execution ...

Boston Scientific continues to deliver robust growth, but valuation limits upside despite strong execution and leading positions in key medical device markets. BSX's growth drivers—Farapulse (PFA), ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Boston Scientific has been ...

For me, buying a publicly traded stock is no different than buying an interest in a private business. In either case, I would only invest in a company that’s well-managed, with a valuable product line ...

Boston Scientific is one of those companies that most people never think about until they need it. Its products are not seen on drugstore shelves or marketed on television. Instead, they sit inside ...

Boston Scientific (BSX) has disclosed a new risk, in the Regulation category. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...

On Wednesday, Boston Scientific Corporation (NYSE:BSX) reported third-quarter 2025 revenues of $5.07 billion, beating the consensus estimate of $4.97 billion. The medical technology giant reported ...

Boston Scientific Corporation, an American producer of medical devices, has expanded its presence in Costa Rica with the opening of a new shared services center in the Zona Franca América, Heredia.

Boston Scientific BSX0.56%increase; green up pointing triangle recorded higher third-quarter sales and raised its full-year earnings guidance on the back of continued growth in its cardiovascular ...

Boston Scientific’s third-quarter revenue topped $5 billion, up 20.3% year over year. Growth eased slightly from the second quarter, when sales rose more than 22%. Urology led the gains, up 28% year ...